Vaccines are designed to guard babies, toddlers, and older children against a whole range of serious and potentially deadly ...

The French drugmaker said it had entered a mandate with an “investment service provider”, with the purchase occurring between ...

Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. Good ...

Government faces healthcare crisis as new physician output drops significantly in Korea New challenges arise as disruptions in medical education threaten Koreas healthcare future.

One Zelienople child survived a serious health scare after coming down with respiratory syncytial virus in late January. The ...

A vaccine designed to help protect babies from the respiratory syncytial virus (RSV) is now free during pregnancy. RSV is the ...

L'Oréal is selling nearly 30 million shares in Sanofi, decreasing its stake in the drugmaker from 9.4% to 7.2%.

Sanofi’s fiscal year 2024 results were in line with expectations, with a noteworthy performance in their Vaccines division, particularly driven by Beyfortus. This offset a slight ...

A successful example of these technologies coming together is Sanofi and AstraZeneca’s Beyfortus (nirsevimab-alip), an anti-RSV monoclonal antibody approved for the prevention of RSV in infants.

This included Beyfortus that achieved blockbuster status ... we have a competitive profile with nirsevimab. We have an extensive amount of real-world evidence. You've seen many countries showing ...

Management expects Beyfortus penetration to grow further with geographic expansion. Gross margin and R&D expenses are also anticipated to increase slightly in 2025, supported by preparations for u ...

As we head into the peak of 2025 RSV season, parents are once again facing an uptick in cases, with health experts warning that the virus could affect more children this year. RSV (respiratory ...